Intrathecal α-conotoxins Vc1.1, AuIB and MII acting on distinct nicotinic receptor subtypes reverse signs of neuropathic pain

[1]  David John Adams,et al.  A novel mechanism of inhibition of high-voltage activated calcium channels by α-conotoxins contributes to relief of nerve injury-induced neuropathic pain , 2011, PAIN®.

[2]  A. Malmberg,et al.  Pharmacological effects of nonselective and subtype-selective nicotinic acetylcholine receptor agonists in animal models of persistent pain , 2010, PAIN®.

[3]  David John Adams,et al.  Analgesic α-conotoxins Vc1.1 and Rg1A inhibit N-type calcium channels in sensory neurons of α9 nicotinic receptor knockout mice , 2010, Channels.

[4]  N. Absalom,et al.  Alpha9 nicotinic acetylcholine receptors and the treatment of pain. , 2009, Biochemical pharmacology.

[5]  J. McIntosh,et al.  Alpha-conotoxins as pharmacological probes of nicotinic acetylcholine receptors , 2009, Acta Pharmacologica Sinica.

[6]  Stephen B. H. Kent,et al.  In situ neutralization in Boc-chemistry solid phase peptide synthesis. Rapid, high yield assembly of difficult sequences. , 2009 .

[7]  Alison Haythornthwaite,et al.  Analgesic α-Conotoxins Vc1.1 and Rg1A Inhibit N-Type Calcium Channels in Rat Sensory Neurons via GABAB Receptor Activation , 2008, The Journal of Neuroscience.

[8]  J. McIntosh,et al.  Spinal α3β2* nicotinic acetylcholine receptors tonically inhibit the transmission of nociceptive mechanical stimuli , 2008, Brain Research.

[9]  M. Quik,et al.  Subtype-selective conopeptides targeted to nicotinic receptors:Concerted discovery and biomedical applications , 2008, Channels.

[10]  J. Boulter,et al.  The α10 nicotinic acetylcholine receptor subunit is required for normal synaptic function and integrity of the olivocochlear system , 2007, Proceedings of the National Academy of Sciences.

[11]  D. Craik,et al.  Are α9α10 Nicotinic Acetylcholine Receptors a Pain Target for α-Conotoxins? , 2007, Molecular Pharmacology.

[12]  J. McIntosh,et al.  Targeting the α9α10 nicotinic acetylcholine receptor to treat severe pain , 2007 .

[13]  J. Changeux,et al.  Evaluating the suitability of nicotinic acetylcholine receptor antibodies for standard immunodetection procedures , 2007, Journal of neurochemistry.

[14]  D. Keays,et al.  Therapeutic applications of conotoxins that target the neuronal nicotinic acetylcholine receptor. , 2006, Toxicon : official journal of the International Society on Toxinology.

[15]  J. McIntosh,et al.  Molecular mechanism for analgesia involving specific antagonism of α9α10 nicotinic acetylcholine receptors , 2006, Proceedings of the National Academy of Sciences.

[16]  D. Craik,et al.  The Synthesis, Structural Characterization, and Receptor Specificity of the α-Conotoxin Vc1.1* , 2006, Journal of Biological Chemistry.

[17]  K. Gayler,et al.  Alpha-conotoxin Vc1.1 alleviates neuropathic pain and accelerates functional recovery of injured neurones , 2005, Brain Research.

[18]  P. M. Lang,et al.  A conus peptide blocks nicotinic receptors of unmyelinated axons in human nerves , 2005, Neuroreport.

[19]  J. Genzen,et al.  Nicotinic modulation of GABAergic synaptic transmission in the spinal cord dorsal horn , 2005, Brain Research.

[20]  J. Changeux,et al.  Nicotine differentially activates inhibitory and excitatory neurons in the dorsal spinal cord , 2004, Pain.

[21]  J. Eisenach,et al.  Plasticity of spinal nicotinic acetylcholine receptors following spinal nerve ligation , 2004, Neuroscience Research.

[22]  T. Deerinck,et al.  Nicotinic acetylcholine receptor distribution in relation to spinal neurotransmission pathways , 2003, The Journal of comparative neurology.

[23]  Z. Khalil,et al.  Drugs from the sea: conotoxins as drug leads for neuropathic pain and other neurological conditions. , 2003, Mini reviews in medicinal chemistry.

[24]  R. Lewis,et al.  Therapeutic potential of venom peptides , 2003, Nature Reviews Drug Discovery.

[25]  D. Keays,et al.  A novel alpha-conotoxin identified by gene sequencing is active in suppressing the vascular response to selective stimulation of sensory nerves in vivo. , 2003, Biochemistry.

[26]  R. Papke,et al.  Modulation of inhibitory synaptic activity by a non-α4β2, non-α7 subtype of nicotinic receptors in the substantia gelatinosa of adult rat spinal cord , 2003, Pain.

[27]  H. Ueda,et al.  Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism , 2002, Brain Research.

[28]  D. Yoshikami,et al.  α-Conotoxin AuIB Selectively Blocks α3β4 Nicotinic Acetylcholine Receptors and Nicotine-Evoked Norepinephrine Release , 1998, The Journal of Neuroscience.

[29]  K. Hole,et al.  Lumbar catheterization of the spinal subarachnoid space in the rat , 1996, Journal of Neuroscience Methods.

[30]  D. Yoshikami,et al.  A New -Conotoxin Which Targets 32 Nicotinic Acetylcholine Receptors (*) , 1996, The Journal of Biological Chemistry.

[31]  Ronald Dubner,et al.  A novel behavioral model of neuropathic pain disorders produced in rats by partial sciatic nerve injury , 1990, Pain.

[32]  A. Ribeiro-da-Silva,et al.  Choline acetyltransferase‐immunoreactive profiles are presynaptic to primary sensory fibers in the rat superficial dorsal horn , 1990, The Journal of comparative neurology.

[33]  D. Craik,et al.  alpha-Conotoxins: nicotinic acetylcholine receptor antagonists as pharmacological tools and potential drug leads. , 2001, Current medicinal chemistry.

[34]  J. McIntosh,et al.  Conus peptides targeted to specific nicotinic acetylcholine receptor subtypes. , 1999, Annual review of biochemistry.

[35]  W. Dixon,et al.  Efficient analysis of experimental observations. , 1980, Annual review of pharmacology and toxicology.